Skip to content
Dose Brief
Menu
No. 222 on the board · Grade C

Ivim Health review

Telehealth weight loss program with low entry-tier semaglutide pricing and a separate program fee for tirzepatide.

Visit Ivim Health Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the score.
Semaglutide
From $75/mo (starting dose, compounded)
Tirzepatide
From $149/mo (starting dose, compounded)
Coverage
Coverage not published
Brand-name
Compounded only
On the trackerNewnew to the tracker, no prior readingNew to the tracker on 1 August 2026. The published line reads From $75/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

The scorecard

Ivim Health scored on our six Brief Score factors. See the methodology.

Price Stability48/100
Supply Reliability74/100
Transparency72/100
Access Breadth50/100
Clinical Oversight79/100
Track Record73/100

What we like

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

The caveats

  • Limited public information on program details

The brief

Best for: Readers who want budget-conscious shoppers. Telehealth weight loss program with low entry-tier semaglutide pricing and a separate program fee for tirzepatide.

Ranked #222 of 495 providers we reviewed — see our #1 pick, CoreAge Rx, for comparison.

Closest on the board

The desks scoring nearest Ivim Health — the realistic shortlist if you're weighing it.

Weighing Ivim Health against one desk in particular? We file it head to head with our top-ranked pick in CoreAge Rx vs Ivim Health, and every desk that outranks it is listed on the Ivim Health alternatives board.

More desks we track (24)

464 more are filed too — see every desk we track, ranked.

Pricing, states and verification reflect Ivim Health's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on Ivim Health's site. Not medical advice; see our disclosure.

← Back to all rankings